Coherus Oncology, Inc.(CHRS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Coherus Oncology, Inc. (CHRS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CHRS at 5.0/100 on a 32-signal composite quality model, placing it at rank #2,955 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.8) and free cash flow (3.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Coherus Oncology, Inc. reports quarterly revenue of $14.3M, net income of $-20.6M. Top institutional holders of CHRS by reported 13-F value include Timothy G. Youngquist 2020 Irrevocable, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CHRS trades on the Nasdaq exchange and files with the SEC under CIK 1512762. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CHRS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Coherus Oncology, Inc. directly from SEC EDGAR.